Date:11/7/2007

atements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company's quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.

Attachment: Financial summary

Atrium Innovations Inc.

Summary of Consolidated Financial Statements

(in millions of US dollars except per share amounts)

Consolidated Results for the 3-month periods ended September 30

(unaudited)

2007 2006 Change

Revenues 100.9 73.3 37.7%

Gross Margin (1) 37.3 21.6 72.8%

37.0% 29.5%

EBITDA (2) 19.2 11.0 74.8%

19.0% 15.0%

Net Earnings 9.8 6.4 52.2%

Net earnings per share

Basic 0.32 0.21

Diluted 0.30 0.20

Cash flow from operating activitie
'/>"/>

SOURCE Atrium Innovations Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Atrium Innovations Announces Management Changes
2. Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer